Logo image of CBLL

CERIBELL INC (CBLL) Stock Fundamental Analysis

USA - NASDAQ:CBLL - US15678C1027 - Common Stock

12.265 USD
+0.49 (+4.12%)
Last: 11/11/2025, 1:00:10 PM
Fundamental Rating

3

CBLL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. The financial health of CBLL is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CBLL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CBLL had negative earnings in the past year.
In the past year CBLL has reported a negative cash flow from operations.
CBLL Yearly Net Income VS EBIT VS OCF VS FCFCBLL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of CBLL (-26.29%) is comparable to the rest of the industry.
With a Return On Equity value of -31.97%, CBLL perfoms like the industry average, outperforming 54.50% of the companies in the same industry.
Industry RankSector Rank
ROA -26.29%
ROE -31.97%
ROIC N/A
ROA(3y)-36.98%
ROA(5y)N/A
ROE(3y)-55.29%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CBLL Yearly ROA, ROE, ROICCBLL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

Looking at the Gross Margin, with a value of 87.99%, CBLL belongs to the top of the industry, outperforming 96.83% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for CBLL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBLL Yearly Profit, Operating, Gross MarginsCBLL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 50 -50 -100

More info and screens

6

2. Health

2.1 Basic Checks

CBLL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CBLL has more shares outstanding
Compared to 1 year ago, CBLL has an improved debt to assets ratio.
CBLL Yearly Shares OutstandingCBLL Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M
CBLL Yearly Total Debt VS Total AssetsCBLL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CBLL has an Altman-Z score of 6.40. This indicates that CBLL is financially healthy and has little risk of bankruptcy at the moment.
CBLL has a Altman-Z score of 6.40. This is amongst the best in the industry. CBLL outperforms 83.07% of its industry peers.
A Debt/Equity ratio of 0.12 indicates that CBLL is not too dependend on debt financing.
CBLL's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. CBLL outperforms 63.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 6.4
ROIC/WACCN/A
WACC8.79%
CBLL Yearly LT Debt VS Equity VS FCFCBLL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

CBLL has a Current Ratio of 12.65. This indicates that CBLL is financially healthy and has no problem in meeting its short term obligations.
CBLL's Current ratio of 12.65 is amongst the best of the industry. CBLL outperforms 96.30% of its industry peers.
CBLL has a Quick Ratio of 12.25. This indicates that CBLL is financially healthy and has no problem in meeting its short term obligations.
CBLL has a Quick ratio of 12.25. This is amongst the best in the industry. CBLL outperforms 97.35% of its industry peers.
Industry RankSector Rank
Current Ratio 12.65
Quick Ratio 12.25
CBLL Yearly Current Assets VS Current LiabilitesCBLL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

CBLL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.29%.
CBLL shows a strong growth in Revenue. In the last year, the Revenue has grown by 44.71%.
EPS 1Y (TTM)-30.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)44.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%31.37%

3.2 Future

CBLL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.29% yearly.
CBLL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.19% yearly.
EPS Next Y29.51%
EPS Next 2Y16.19%
EPS Next 3Y16.29%
EPS Next 5YN/A
Revenue Next Year35.36%
Revenue Next 2Y31.75%
Revenue Next 3Y31.4%
Revenue Next 5Y33.19%

3.3 Evolution

CBLL Yearly Revenue VS EstimatesCBLL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
CBLL Yearly EPS VS EstimatesCBLL Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CBLL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBLL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBLL Price Earnings VS Forward Price EarningsCBLL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBLL Per share dataCBLL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

CBLL's earnings are expected to grow with 16.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.19%
EPS Next 3Y16.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CBLL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERIBELL INC

NASDAQ:CBLL (11/11/2025, 1:00:10 PM)

12.265

+0.49 (+4.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-23 2026-02-23
Inst Owners73.62%
Inst Owner Change2.61%
Ins Owners10.59%
Ins Owner Change2.99%
Market Cap449.63M
Revenue(TTM)82.81M
Net Income(TTM)-52.46M
Analysts88.57
Price Target30.26 (146.72%)
Short Float %4.93%
Short Ratio5.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.7%
Min EPS beat(2)5.13%
Max EPS beat(2)12.27%
EPS beat(4)3
Avg EPS beat(4)2.68%
Min EPS beat(4)-23.32%
Max EPS beat(4)16.63%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.65%
Min Revenue beat(2)1.62%
Max Revenue beat(2)1.68%
Revenue beat(4)4
Avg Revenue beat(4)2.8%
Min Revenue beat(4)1.62%
Max Revenue beat(4)4.36%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.71%
PT rev (3m)-6.71%
EPS NQ rev (1m)0.46%
EPS NQ rev (3m)-12.98%
EPS NY rev (1m)0.18%
EPS NY rev (3m)-0.44%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.57%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)1.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.43
P/FCF N/A
P/OCF N/A
P/B 2.74
P/tB 2.74
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS2.26
BVpS4.48
TBVpS4.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.29%
ROE -31.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.99%
FCFM N/A
ROA(3y)-36.98%
ROA(5y)N/A
ROE(3y)-55.29%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 103.47%
Cap/Sales 1.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.65
Quick Ratio 12.25
Altman-Z 6.4
F-Score5
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)209.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.91%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y29.51%
EPS Next 2Y16.19%
EPS Next 3Y16.29%
EPS Next 5YN/A
Revenue 1Y (TTM)44.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%31.37%
Revenue Next Year35.36%
Revenue Next 2Y31.75%
Revenue Next 3Y31.4%
Revenue Next 5Y33.19%
EBIT growth 1Y-32.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-44.99%
EBIT Next 3Y17.12%
EBIT Next 5YN/A
FCF growth 1Y-18.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.18%
OCF growth 3YN/A
OCF growth 5YN/A

CERIBELL INC / CBLL FAQ

Can you provide the ChartMill fundamental rating for CERIBELL INC?

ChartMill assigns a fundamental rating of 3 / 10 to CBLL.


What is the valuation status for CBLL stock?

ChartMill assigns a valuation rating of 0 / 10 to CERIBELL INC (CBLL). This can be considered as Overvalued.


What is the profitability of CBLL stock?

CERIBELL INC (CBLL) has a profitability rating of 1 / 10.